Par's generic carisoprodol/aspirin

Executive Summary

Firm received approval for the combination tablet formulation March 31. Carter-Wallace markets the muscle relaxant under the brand name Soma Compound, with estimated sales at $10 mil., Par said in an April 5 release. FDA had approved Par's ANDA June 7, 1988, but subsequently rescinded approval because of possible infringement on Carter-Wallace's formulation patent scheduled to expire 2002. Par has since certified that its generic does not infringe on the patent. Par is the second generic company to receive an ANDA approval for the combination product, following Bolar's approval in 1985.